In short · mixed
The healthcare and pharmaceutical sector saw mixed developments, highlighted by Grail shares jumping 33% following favorable FDA briefing documents for its Galleri cancer test. Boryung secured a $277.14 million supply deal in China, and Enveda Biosciences raised $311 million for its AI-driven pipeline. However, Immunovant dropped a lupus program after a Phase 2b failure, and Novo Nordisk shares fell 7% despite outlining long-term growth targets.
This brief
7 stories on Healthcare & Pharma
The Market Overview is open to everyone. The Healthcare & Pharma brief - and every other one - needs an account, which is free and keeps your place, your streak and the terms you save.
Free · no card